Navigation Links
Phase 3 Data Show Intravenous Golimumab Inhibited Radiographic Progression in Patients with Active Rheumatoid Arthritis
Date:11/12/2012

ur or get worse in people who use TNF blockers, including SIMPONI®. Your doctor will closely monitor you if you have heart failure. Tell your doctor right away if you get new or worsening symptoms of heart failure like shortness of breath or swelling of your lower legs or feet. 

Rarely, people using TNF blockers, including SIMPONI®, can have nervous system problems such as multiple sclerosis or Guillain-Barre syndrome. Tell your doctor right away if you have symptoms like vision changes, weakness in your arms or legs, or numbness or tingling in any part of your body.  

Serious liver problems can happen in people using TNF blockers, including SIMPONI®. Contact your doctor immediately if you develop symptoms such as feeling very tired, skin or eyes look yellow, poor appetite or vomiting, or pain on the right side of your stomach.

Low blood counts have been seen with people using TNF blockers, including SIMPONI®. If this occurs, your body may not make enough blood cells to help fight infections or help stop bleeding. Your doctor will check your blood counts before and during treatment. Tell your doctor if you have signs such as fever, bruising, bleeding easily, or paleness.

Rarely, people using TNF blockers have developed lupus-like symptoms. Tell your doctor if you have any symptoms such as a rash on your cheeks or other parts of the body, sensitivity to the sun, new joint or muscle pain, becoming very tired, chest pain or shortness of breath, swelling of the feet, ankles, and/or legs.

New or worse psoriasis symptoms may occur. Tell your doctor if you develop red scaly patches or raised bumps that are filled with pus.  

Tell your doctor if you are pregnant, planning to become pregnant or are breastfeeding or have a baby and were using SIMPONI® during pregnancy. Tell your baby's doctor before your baby receives any vacci
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Aug. 1, 2014  NxStage Medical, Inc. (Nasdaq: ... announced that Jeffrey H. Burbank , Chief Executive Officer, ... at the 34 th Annual Canaccord Genuity Growth Conference ... , on Wednesday, August 13 th at 4:30 ... available at http://ir.nxstage.com/ .  About NxStage ...
(Date:8/1/2014)... HYDERABAD, India , Aug. 1, 2014 /PRNewswire/ ... manufacturer providing active pharmaceutical ingredients (APIs), ... to customers located in 85 countries, today announced ... year (FY) 2015, ended June 30, 2014. ... affected by work flow re-prioritization to accommodate certain ...
(Date:8/1/2014)... JUPITER, Fla. , Aug. 1, 2014 ... company whose patented and proprietary technologies are used to ... the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, ... for the second quarter ended June 30, 2014 after ... host a conference call that day at 5:00 p.m. ...
Breaking Medicine Technology:NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 2Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 3Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 3
... April 29, 2011 Halozyme Therapeutics, Inc. (Nasdaq: ... products targeting the extracellular matrix , today announced ... on Friday, May 6, 2011 before the open of ... a conference call with the investment community at 8:00 ...
... SAN MATEO, Calif., April 29, 2011 ... patch purchased by 321 institutions, up from 239 in Q4 ... Qutenza product revenue Operational focus enables lower planned expense ... Czech Republic by Astellas NGX-1998 Phase 2 clinical trial ...
Cached Medicine Technology:Halozyme Therapeutics to Host First Quarter 2011 Financial Results Conference Call on May 6 2NeurogesX Reports First Quarter 2011 Results 2NeurogesX Reports First Quarter 2011 Results 3NeurogesX Reports First Quarter 2011 Results 4NeurogesX Reports First Quarter 2011 Results 5NeurogesX Reports First Quarter 2011 Results 6NeurogesX Reports First Quarter 2011 Results 7NeurogesX Reports First Quarter 2011 Results 8
(Date:8/1/2014)... 2014 The Judicial Panel on Multidistrict ... replacement therapy caused strokes, heart attacks, and other injuries ... Matthew F. Kennelly as the transferee judge and ordered ... Chicago-based federal court. , As one of his first ... committees of attorneys who will move the litigation forward ...
(Date:8/1/2014)... New research at Washington University School of Medicine in ... often in males and frequently are more harmful than ... common malignant brain tumors, are diagnosed twice as often ... and do not survive as long. , The researchers ... reduce cancer risk, is significantly less active in male ...
(Date:8/1/2014)... New York (PRWEB) August 01, 2014 ... protecting the rights of victims injured by defective medical ... it would be recalling its Ethicon surgical power morcellator ... device maker sited concerns involving the spread of cancer ... report dated July 31, 2014. , Johnson ...
(Date:8/1/2014)... York, New York (PRWEB) August 01, 2014 ... filed in the wake of the 2012 Rejuvenate ... to move forward in New Jersey’s Bergen County ... documents filed in the proceeding, the Court has ... of Confidentiality governing any and all hard copy ...
(Date:8/1/2014)... Aug. 1, 2014 (HealthDay News) -- Almost 140 ... school transportation in the United States. But ... bus-related catastrophes, Dawne Gardner, injury prevention coordinator at ... Center, said in a medical center news release. ... returning to school, it,s important for parents and ...
Breaking Medicine News(10 mins):Health News:Judge Kennelly Appoints Attorney Michelle Kranz to the Plaintiffs’ Executive Committee in the Testosterone Replacement Therapy MDL 2Health News:Study reveals one reason brain tumors are more common in men 2Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 2Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 3Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 4Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:Expert Offers School Bus Safety Tips 2
... Preserves Competition for Medicare Advantage,Plans Sold to Senior ... of,Justice announced today that it will require UnitedHealth ... to divest assets relating,to United,s Medicare Advantage business ... with United,s acquisition of Sierra. The Department said ...
... An article co-authored by Susan L. Mitchell, M.D., ... reports that nursing home residents with advanced dementia ... two weeks before death. This practice raises concerns ... with advanced dementia, as well as the emergence ...
... place burden on Medicare, analysis finds , , MONDAY, Feb. ... Americans newly diagnosed with heart failure has declined, the ... new research finds. , The Duke University study analyzed ... diagnosed with heart failure between 1994 and 2003. It ...
... Combined hormone therapy appears to increase the risk that ... it may decrease the effectiveness of both methods for ... Feb. 25 issue of Archives of Internal Medicine, one ... Ph.D., a lead investigator at the Los Angeles Biomedical ...
... 20 percent of patients taking aspirin to lower the ... have an antiplatelet response from aspirin, the effect thought ... at Buffalo have shown. , Millions of people ... stroke, second heart attack or second episode of peripheral ...
... a Systems Biology company focussed on high quality annotation ... its abilities in the analysis of data generated by ... et al published in the January 2008 issue of ... Open Chromatin across the Genome where they identified DNase ...
Cached Medicine News:Health News:Justice Department Requires Divestiture in UnitedHealth Group's Acquisition of Sierra Health Services 2Health News:Justice Department Requires Divestiture in UnitedHealth Group's Acquisition of Sierra Health Services 3Health News:Hebrew SeniorLife researcher finds 2Health News:Hebrew SeniorLife researcher finds 3Health News:More Elderly Americans Living With Heart Failure 2Health News:LA BioMed study finds hormone therapy increases frequency of abnormal mammograms, breast biopsies 2Health News:Many stroke, heart attack patients may not benefit from aspirin 2Health News:Many stroke, heart attack patients may not benefit from aspirin 3Health News:Genomatix integrates genome-wide open chromatin from next generation sequencing 2
POLYSORB™ sutures are composed of LACTOMER™ glycolide/lactide copolymer which is a synthetic polyester composed of glycolide and lactide (derived from glycolic and lactic acids)....
Surgitie&trade Single Use Ligating Loops with Delivery System...
ENDO SLIDE™ single use knot pusher with 12 units per box....
ENDO STITCH™ Single Use Loading Units....
Medicine Products: